Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$1.50 USD
+0.28 (22.95%)
Updated Sep 26, 2025 04:00 PM ET
After-Market: $1.51 +0.01 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRLD 1.50 +0.28(22.95%)
Will PRLD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRLD
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
PRLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
Other News for PRLD
Is PRLD showing upside potential? New Uptrend shows up after soaring 22.95%
PRLD rises 4.27% on September 25, leaving the technical picture intact
Is PRLD positioned for a breakout? Crossed Above 20 Day Moving Average shows up after rallying 13.59%
Stochastic Buy Signal appears for PRLD after 1.98% move
Crossed Above 50 Day Moving Average appears for PRLD after 2.56% move